Elosulfase alfa · VIMIZIM

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Mucopolysaccharidosis Type IVA

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
CN
  • MPS IVA (Morquio A syndrome)
Product first approved 2019biomarin.com
JP
  • MPS IVA (Morquio A syndrome)
Product first approved 2014biomarin.com
EU
  • Mucopolysaccharidosis type IVA (Morquio A syndrome)
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT01966029 · BioMarin Pharmaceutical
2013-07 – 2016-12 · Mucopolysaccharidosis IVA (Morquio A Syndrome)
What this study did
Phase 2 (3)
Other / comorbidity
NCT01515956 · BioMarin Pharmaceutical
2011-10 – 2016-02 · Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
What this study did
NCT01609062 · BioMarin Pharmaceutical
2012-04 – 2014-11 · Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
What this study did
NCT01697319 · BioMarin Pharmaceutical
2012-08 – 2014-10 · Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT01242111 · BioMarin Pharmaceutical
2010-11 – 2014-07 · MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome
What this study did
NCT00884949 · BioMarin Pharmaceutical
2009-04 – 2011-03 · MPS IV A
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.